Like we mentioned a moment ago, it used to be the belief that “pure CBD,” or CBD isolate, packed the most potent punch in terms of cannabis therapy. And that would make sense too, right? If we know that CBD is primarily the active compound in the plant that provides the medical relief and therapy, then wouldn’t it make sense to make a 100% pure powder out of it?
Dosage is important, because CBD can have side effects—the most common are tiredness, diarrhea, and changes in appetite and weight—so it’s best not to take more than you need. As CBD becomes more prevalent, says J. Michael Bostwick, M.D., a psychiatrist at Mayo Clinic in Rochester, MN, “I’m reasonably certain new kinds of side effects will emerge.”
After seasonal harvests of specific cultivars, these high-CBD hemp crops are put through a specialized solvent-free extraction process to yield a hemp oil that is naturally high in cannabidiol. This high CBD oil is different from hemp oil that is used in cooking. This pure hemp extract is then tested for safety, quality, and cannabinoid content before being exported to our processing facilities in the United States. Importing any cannabis or hemp product into the United States is a complicated and serious task, so we leave nothing to chance before our high-CBD hemp oil makes its journey across the Atlantic Ocean.
Given CBD’s reputation as a popular, artisanal remedy, one would think that Epidiolex would command a lot of “off label” attention. After all, physicians often prescribe pharmaceuticals off label to treat conditions that were not the actual focus of clinical trials. But the costly price tag for Epidiolex (more than $30,000 annually) precludes off label prescribing as well as affordable access for tens of millions of Americans without health insurance.
Cutting-edge science has shown that the endocannabinoid system is dysregulated in nearly all pathological conditions. Thus, it stands to reason that “modulating endocannabinoid system activity may have therapeutic potential in almost all diseases affecting humans,” as Pal Pacher and George Kunos, scientists with the U.S. National Institutes of Health (NIH), suggested in a 2014 publication.